This is the third generic western medicine to be included in Tianyin’s product portfolio. The company will continue to diversify its traditional Chinese medicine products, with additional western medicines as they receive approvals for the 10 drugs that are currently in the SFDA pipeline. Azithromycin is highly effective in treating upper and lower respiratory tract infections and other bacterial infections in skins and reproductive system.
The largest domestic distributor of Azithromycin, Anhui Huayuan Pharmaceutical is currently one of Tianyin’s top strategic partners and has awarded the company a $3.66 million distribution contract for 2008 covering most of the PRC for Azithromycin and other products. This collaboration will help speed the market entry of Tianyin’s Azithromycin dispersible tablets and enable the company to leverage its national SFDA manufacturing approval to gain market share throughout China.
Guoqing Jiang, chairman and CEO of Tianyin, said: “We believe that the launch of Azithromycin provides the opportunity for significant growth in both sales revenue and net profit in the coming years.”